Australian MDx Firm Genetic Signatures Eyes IPO for up to A$15M | GenomeWeb

NEW YORK (GenomeWeb) – Australian molecular diagnostics firm Genetic Signatures today said that it plans to offer up to A$15 million (US$13.1 million) of its shares in an initial public offering.

The firm said in a prospectus that it seeks to raise between A$12 million (US$10.5 million) and A$15 million through an offering of up to 37.5 million shares of its stock at A$.40 per share. Proceeds will be used primarily to fund expansion into the European and US markets and the development of additional products, according to the company's prospectus.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.